Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD21 trial of BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma
NL-OMON50640Phase 3Recruiting
- Sponsor
- University of Cologne
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin, bleomycin, etoposide, doxorubicin, cyclophosphamide and 5 more in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by University of Cologne. Primary endpoints: Progression-free survival, Serious treatment-related toxicity rate during primary treatment and 1 more. Started Mar 2018; status: recruiting.
02
Drugs
brentuximab vedotinbleomycinetoposidedoxorubicincyclophosphamide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON50640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50640.